4 results on '"Dennis W. Simon"'
Search Results
2. Feasibility and Performance of a Gel-Adhesive Pad System for Pediatric Targeted Temperature Management: An Exploratory Analysis of 19 Pediatric Critically Ill Patients
- Author
-
Ericka L. Fink, Rajesh K. Aneja, Rebecca Lavezoli, Cameron Dezfulian, Robert S. B. Clark, Patrick M. Kochanek, Alicia M. Alcamo, and Dennis W. Simon
- Subjects
medicine.medical_specialty ,business.industry ,Critically ill ,Critical Illness ,medicine.medical_treatment ,Temperature ,Neurointensive care ,Original Articles ,Exploratory analysis ,Targeted temperature management ,Critical Care and Intensive Care Medicine ,Body Temperature ,Anesthesiology and Pain Medicine ,Hypothermia, Induced ,Treatment modality ,Adhesives ,Feasibility Studies ,Humans ,Medicine ,Child ,business ,Intensive care medicine ,Surface cooling - Abstract
Targeted temperature management (TTM) is an important treatment modality in pediatric neurocritical care. There are different types of devices available to deliver this therapy, but limited pediatric data exist. This quality improvement study evaluates the use of a surface cooling device that uses gel-adhesive pads for TTM in critically ill pediatric patients. An institutional TTM protocol to use the gel-adhesive pad system was developed with three different temperature goals: normothermia (goal temperature 37°C), mild hypothermia (goal temperature 35°C with rewarming duration of 12 hours to normothermia), and moderate hypothermia (goal temperature 33°C with rewarming duration of 24 hours to normothermia). Protocol and device implementation required several different educational sessions for all members of the critical care team. An exploratory analysis was performed for 19 patients with complete clinical and device temperature data. The most common protocol used was normothermia (73.6%). By protocol, time to goal temperature was 58 minutes (22.0–112.8) for normothermia, 46.5 minutes (44.3–48.8) for mild hypothermia, and 93 minutes (46.5–406.5) for moderate hypothermia. Patients remained within ±0.5°C temperature goal 99% (96.0–99.3) of the time in the normothermia protocol, 99.5% (99–100) in mild hypothermia, and 93% (80–100) for the moderate hypothermia protocol. Shivering was the most common adverse event (35%). Our results show that use of the gel-adhesive pad system for pediatric TTM is feasible, efficacious with regard to achieving both a short time to target temperature and maintaining temperature goal, and, in this limited sample, was free from major adverse events. We also defined several technical aspects of device use in pediatric patients that should be considered in future trial design and/or clinical use. Further studies are needed to determine if this device is superior to other cooling devices for temperature management in the pediatric population.
- Published
- 2021
3. Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision
- Author
-
Samuel M. Poloyac, Patrick M. Kochanek, Shaun W. Carlson, Milos D. Ikonomovic, Edwin K. Jackson, Ava M. Puccio, Amery Treble-Barna, Corina O. Bondi, Michael J. Bell, Alicia K. Au, Ruchira M. Jha, Hülya Bayır, D. Lansing Taylor, Dennis W. Simon, Yvette P. Conley, Jonathan Elmer, Valerian E. Kagan, Stephen R. Wisniewski, Lori Shutter, Philip E. Empey, Robert S. B. Clark, Anthony E. Kline, Amy K. Wagner, Christopher M. Horvat, Travis C. Jackson, Steven H. Graham, C. Edward Dixon, Andrew M. Stern, and David O. Okonkwo
- Subjects
030506 rehabilitation ,medicine.medical_specialty ,Combination therapy ,Traumatic brain injury ,medicine.medical_treatment ,Translational Research, Biomedical ,03 medical and health sciences ,0302 clinical medicine ,Brain Injuries, Traumatic ,Concussion ,Animals ,Humans ,Medicine ,Intensive care medicine ,Coma ,Rehabilitation ,business.industry ,Clinical study design ,Glasgow Coma Scale ,Original Articles ,medicine.disease ,Precision medicine ,Neuroprotective Agents ,Neurology (clinical) ,medicine.symptom ,0305 other medical science ,business ,030217 neurology & neurosurgery - Abstract
New neuroprotective therapies for severe traumatic brain injury (TBI) have not translated from pre-clinical to clinical success. Numerous explanations have been suggested in both the pre-clinical and clinical arenas. Coverage of TBI in the lay press has reinvigorated interest, creating a golden age of TBI research with innovative strategies to circumvent roadblocks. We discuss the need for more robust therapies. We present concepts for traditional and novel approaches to defining therapeutic targets. We review lessons learned from the ongoing work of the pre-clinical drug and biomarker screening consortium Operation Brain Trauma Therapy and suggest ways to further enhance pre-clinical consortia. Biomarkers have emerged that empower choice and assessment of target engagement by candidate therapies. Drug combinations may be needed, and it may require moving beyond conventional drug therapies. Precision medicine may also link the right therapy to the right patient, including new approaches to TBI classification beyond the Glasgow Coma Scale or anatomical phenotyping-incorporating new genetic and physiologic approaches. Therapeutic breakthroughs may also come from alternative approaches in clinical investigation (comparative effectiveness, adaptive trial design, use of the electronic medical record, and big data). The full continuum of care must also be represented in translational studies, given the important clinical role of pre-hospital events, extracerebral insults in the intensive care unit, and rehabilitation. TBI research from concussion to coma can cross-pollinate and further advancement of new therapies. Misconceptions can stifle/misdirect TBI research and deserve special attention. Finally, we synthesize an approach to deliver therapeutic breakthroughs in this golden age of TBI research.
- Published
- 2020
4. Minocycline Attenuates High Mobility Group Box 1 Translocation, Microglial Activation, and Thalamic Neurodegeneration after Traumatic Brain Injury in Post-Natal Day 17 Rats
- Author
-
Rajesh K. Aneja, Patrick M. Kochanek, Robert B. Clark, Dennis W. Simon, Hülya Bayır, Henry Alexander, and Michael J. Bell
- Subjects
Male ,0301 basic medicine ,Traumatic brain injury ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Minocycline ,Stereology ,Pharmacology ,HMGB1 ,Rats, Sprague-Dawley ,03 medical and health sciences ,0302 clinical medicine ,Thalamus ,Brain Injuries, Traumatic ,medicine ,Animals ,HMGB1 Protein ,Craniotomy ,Neuroinflammation ,biology ,Microglia ,business.industry ,Neurodegeneration ,Original Articles ,medicine.disease ,Rats ,030104 developmental biology ,medicine.anatomical_structure ,Anesthesia ,Nerve Degeneration ,biology.protein ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
In response to cell injury, the danger signal high mobility group box-1 (HMGB) is released, activating macrophages by binding pattern recognition receptors. We investigated the role of the anti-inflammatory drug minocycline in attenuating HMGB1 translocation, microglial activation, and neuronal injury in a rat model of pediatric traumatic brain injury (TBI). Post-natal day 17 Sprague-Dawley rats underwent moderate-severe controlled cortical impact (CCI). Animals were randomized to treatment with minocycline (90 mg/kg, intraperitoneally) or vehicle (saline) at 10 min and 20 h after injury. Shams received anesthesia and craniotomy. We analyzed HMGB1 translocation (protein fractionation and Western blotting), microglial activation (Iba-1 immunohistochemistry), neuronal death (Fluoro-Jade-B [FJB] immunofluorescence), and neuronal cell counts (unbiased stereology). Behavioral assessments included motor and Morris-water maze testing. Nuclear to cytosolic translocation of HMGB1 in the injured brain was attenuated in minocycline versus vehicle-treated rats at 24 h (p
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.